Caroline Copley

ZURICH (Reuters) - Delays in developing copies of Roche's top-selling biotech drug are justifying the Swiss company's decision to stay out of biotech generics to focus on improved, patented versions...

ZURICH (Reuters) - Novartis could produce 14 or more new big-selling 'blockbuster' drugs within five years as it bets on cancer, heart and respiratory treatments to fill the gaps left...

ZURICH (Reuters) - Novartis could produce 14 or more new big-selling 'blockbuster' drugs within five years as it bets on cancer, heart and respiratory treatments to fill the gaps left...

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments...

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG is banking on a new generation of breast cancer medicines to drive sales growth after strong demand for its established cancer treatments...

LONDON (Reuters) - Swiss drugmaker Roche Holding AG expects results from 19 late-stage clinical trials over the next 18 months, providing a stream of products to offset a potential near-term...

LONDON (Reuters) - Swiss drugmaker Roche Holding AG expects results from 19 late-stage clinical trials over the next 18 months, providing a stream of products to offset a potential near-term...

LONDON (Reuters) - Swiss drugmaker Roche Holding AG expects results from 19 late-stage clinical trials over the next 18 months, providing a stream of products to offset a potential near-term...